Developing STK-001: An Oligonucleotide Treatment for Dravet Syndrome, Treatment Beyond Seizure Control

Time: 11:40 am
day: Day Two


  • Exploring the clinical trial design and global expansion for STK-001
  • Assessing the enrolment, dosing strategies and secondary endpoints chosen
  • Evaluating safety and pharmacokinetic data from the SAD portion of the MONARCH study